Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection

• Status: Not yet recruiting
• Trial end date: 2026-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To learn if Hyperpolarized C-Pyruvate Magnetic Resonance (HP-MR) Spectroscopic Imaging can help doctors detect low-risk (benign) and high-risk (malignant) cysts.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center

Criteria

Inclusion Criteria:

• Patients ≥ 18 years old. Patients under 18 are excluded due to their potential inability to understand and consent independently to the methods required for the study drug use and its potential risks and benefits.

• Patients with pancreatic cyst/s

• Patients who will undergo surgical resection (or cyst wall biopsy) of pancreatic cysts

• Patients able to understand and willing to sign a written informed consent document

• Both English-speaking and non-English-speaking patients are eligible for participation

Exclusion Criteria:

• Contraindication to MRI

• Electrically, magnetically, or mechanically activated implants that would preclude MRI

• Allergy to Gadavist IV contrast

• History of cardiac arrhythmias

• Pregnancy or breastfeeding women

• Women of child-bearing age that are sexually active and not using birth control

• Cognitively impaired individuals

• Weight above 260 pounds (lbs)